Allon Therapeutics product AL-108 successful in Phase Ia clinical trial

20-Jun-2005

Allon Therapeutics Inc., The Neuro Protection Company(TM), announced that a Phase Ia human clinical trial of the company's first product AL-108 has demonstrated that a single dose administered at up to 15 milligrams was safe and well tolerated in healthy adults. AL-108 is being developed as a treatment for Alzheimer's disease.

Gordon McCauley, President and CEO of Allon, said the next step in the clinical evaluation of AL-108 is a Phase Ib clinical trial with healthy elderly subjects scheduled to begin in Q3 2005. The trial is expected to be completed in Q4 2005 and results available early in Q1 2006.

"This Phase Ia trial has been a complete success," McCauley said. "AL-108 appears to be safe, well tolerated and no serious adverse events were reported. None of the chemistry, hematology or urinalysis laboratory results was considered to be clinically significant by the principal investigator. Furthermore, there were no clinically significant changes in electrocardiograms or vital signs measured in any subject during the observation period."

https://www.bionity.com/en/news/46948/allon-therapeutics-product-al-108-successful-in-phase-ia-clinical-trial.html